Published in Anti-Infectives Week, March 15th, 2004
The clinical trial will compare the efficacy of a single dose of Hyphanox, formerly referred to as Sporamelt, to a single 150 mg dose of the antifungal fluconazole, a currently available standard oral treatment. A 150 mg tablet of fluconazole for the treatment of vaginal candidiasis is currently sold in the United States by Pfizer, Inc., under the brand name Diflucan.
Barrier expects to enroll approximately 900 patients at 40...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.